Toxic Neuropathy Consortium (TNC) – Special interest Group
of the Peripheral Nerve Society
Exposure to toxic agents (anticancer drugs, alcohol, environmental and industrial pollutants …) is among the most frequent causes of peripheral nerve damage, requiring a multi-disciplinary collaboration for proper investigation and assessment.
The Toxic Neuropathy Consortium was created as aSpecial Interest Group of the PNS at the 2018 meeting in Baltimore. We aim at increasing the engagement of all the relevant stakeholders (basic researcher, physicians, nurses, patients, health organizations and agencies as well as pharmaceutical companies), in order to improve knowledge and find solutions to the medical and social problems related to toxic neuropathies.
These goals will be realized by cooperation, supporting research, revising scientific evidence and clinical needs, training scientists and healthcare professionals, setting standards of care, creating new treatments, and facilitating clinical trials.
The following is the TNC by-law.
Article I. MISSION
The TNC is a Standing Committee of the Peripheral Nerve Society. The organizing committee is composed of scientists who are committed to improving and advancing the investigation and treatment of toxic neuropathies.
The mission of the TNC is to increase and improve research and knowledge on toxic neuropathies in order to ameliorate the care and treatment of patients.
ARTICLE II. TNC BOARD
Section 1: Number and Composition of the Board: The Board shall be composed of six (6) board members, including three (3) elected board members and three (3) Officers of the Group– the Chair, the Vice Chair, and the Secretary.
Section 2: Term and Election of the Board: Each TNC Board member will be elected for a four-year term. The Chair, the Vice Chair and the Secretary will serve for a term of four (4) years.
Section 3: Resignation: Any Board Member may resign upon presenting to the Board his/her resignation in writing or by email.
Section 4: Removal from Office: Any Board Member may be removed from the Board by the affirmative vote of two-thirds (2/3) of the Board at any meeting thereof, upon written notice setting forth the reasons and grounds thereof, at least thirty (30) days prior to the date of such meeting. The individual will be notified via e-mail.
Section 5: Vacancies: Should any Board member die, resign, retire, be removed or disqualified, or otherwise vacate his/her office, the position will be filled by a TNC member, in good standing and selected by the TNC Officers until a new member is nominated and elected by membership during the next call for nominations to fill the unexpired term and up to a maximum of 4 years in total time being determined by the timing of the next vote for Board members
Section 6: Quorum. Four (4) members of the Board present and voting shall constitute a quorum.
ARTICLE III. OFFICERS
Section 1: Officers: The Officers of the Society shall be the Chair, the Vice Chair, and the Secretary.
Section 2: Chair: The Chair of the TNC will serve as a non-voting member of the PNS Board of Directors.
ARTICLE IX. MEMBERSHIP
Membership of the TNC of the Peripheral Nerve Society is open to any member of the Peripheral Nerve Society who is engaged in research into the cause or treatment of toxic agent-induced diseases of the peripheral nervous system.
Interested individuals should indicate their interest when paying their membership dues.
ARTICLE X. MEETINGS
The TNC will meet at the annual PNS meeting as a minimum and may meet at other times as member’s desire.
Notices of the TNC meetings will be posted on the PNS website
ARTICLE XI. MISCELLANEOUS
Section 1: Trial evidence: The TNC will collaborate in keeping an up-to-date account of the current trial evidence also supporting the Cochrane Collaboration in performing systematic reviews of randomised trials.
Section 2: Patient register: The TNC will collaborate in establishing registries of patients with certain uncommon, but defined, toxic-mediated neuropathies.
Section 3: Prioritisation of trials: The TNC will prioritise interventions for future trials and attempt to facilitate development of prioritised trials.
Section 4: Communication: The TNC will seek status as an ad hoc committee of the Peripheral Nerve Society, hold meetings open to members of the Peripheral Nerve Society, maintain a page on the Peripheral Nerve Society web site, seek publication of its recommendations in the Journal of the Peripheral Nervous System, and provide updates of its activities in the newsletters.
Section 5: Liaison: The TNC will liaise with interested pharmaceutical companies to achieve its mission. It will work closely with relevant patient organizations to ensure the relevance of its work to the needs of people with toxic-mediated neuropathy.
Section 6: Funding: The TNC may apply to the PNS and other organizations for funds to support its activities.